Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
JTO Clinical and Research Reports|December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 TrialValérie Gounant, Laurent Greillier, Céline Mascaux, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2024
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU studyMarion Ferreira, Aurélie Swalduz, Laurent Greillier, et al.
Journal of Geriatric Oncology|May 19, 2022
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancerAnne-Laure Couderc, Laetitia Ninove, Emilie Nouguerède, et al.
Trials|January 17, 2019
PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trialAnne-Laure Couderc, Emilie Nouguerède, Karine Baumstarck, et al.
The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
JTO Clinical and Research Reports|December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 TrialValérie Gounant, Laurent Greillier, Céline Mascaux, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2024
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU studyMarion Ferreira, Aurélie Swalduz, Laurent Greillier, et al.
Journal of Geriatric Oncology|May 19, 2022
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancerAnne-Laure Couderc, Laetitia Ninove, Emilie Nouguerède, et al.
Trials|January 17, 2019
PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trialAnne-Laure Couderc, Emilie Nouguerède, Karine Baumstarck, et al.
The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018Olivier Bylicki, Pascale Tomasini, Gervais Radj, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
Pageof 16